Farber's Disease Market Report 2026

The farber's disease market size has grown strongly in recent years. It will grow from $1.98 billion in 2025 to $2.1 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rare disease identification, pediatric genetic testing, supportive care protocols, hospital specialization, research funding.

The farber's disease market size is expected to see strong growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to gene therapy pipelines, orphan drug incentives, early diagnosis programs, rare disease registries, advanced genetic tools. Major trends in the forecast period include increased focus on rare pediatric disorders, expansion of gene therapy research, growing supportive care adoption, multidisciplinary treatment approaches, improved genetic diagnostics.

The growing prevalence of rare genetic diseases is expected to propel the growth of the Farber’s disease market in the coming years. Rare genetic diseases are inherited disorders caused by mutations in a person’s DNA that affect a very small percentage of the population. The rising prevalence of these diseases is driven by improved diagnostic technologies, enabling earlier and more accurate identification of conditions that were previously undiagnosed or misdiagnosed. Farber’s disease serves as a model for developing targeted therapies and advancing research in enzyme replacement treatments for ultra-rare conditions. For instance, in February 2023, according to the European Commission (EC), a Belgium-based government entity, up to 36 million people in the European Union live with a rare disease; there are more than 6,000 distinct rare diseases in the EU, with around 80% being of genetic origin. Therefore, the growing prevalence of rare genetic diseases is driving the growth of the Farber’s disease market.

The rising adoption of home-care and telehealth models is expected to further propel the Farber’s disease market. Home-care and telehealth models are healthcare delivery systems that provide medical services, monitoring, and treatment in patients’ residences through in-person nursing visits or remote digital consultations, reducing reliance on hospital-based care. The adoption of these models is increasing due to healthcare system efforts to reduce costs and improve patient convenience, especially following pandemic-era digital health expansions. Home-care and telehealth enable expanded access to specialized treatments and regular monitoring for rare disease patients who require continuous medical oversight but may face difficulties traveling to specialty centers for frequent consultations. For instance, in April 2023, according to FAIR Health Inc., a US-based non-profit organization, national telehealth use increased by 7.3%, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Therefore, the growing adoption of home-care and telehealth models is driving the growth of the Farber’s disease market.

The increasing investment in clinical trials is expected to further boost the Farber’s disease market. Clinical trials are research studies conducted in humans to evaluate the safety, effectiveness, and outcomes of medical interventions, including drugs, treatments, or devices. Investment in clinical trials is rising due to the growing demand for innovative treatments, driven by advances in medical science, personalized medicine, and the need to address unmet healthcare needs. Farber’s disease underscores the importance of research into rare and underserved genetic disorders, encouraging investment in novel therapeutic development. For instance, in October 2024, according to Citeline, a US-based pharma intelligence solutions provider, TrialTrove captured 9,959 Phase I-III clinical trials with a 2024 start date investigating at least one drug, representing a 9.4% increase from 2023. Therefore, increasing investment in clinical trials is driving the growth of the Farber’s disease market.

Major companies operating in the farber's disease market are National Institutes of Health (NIH), U.S. National Institute of Neurological Disorders and Stroke (NINDS), Mount Sinai Icahn School of Medicine, Cincinnati Children’s Hospital Medical Center, University of Pennsylvania Gene Therapy Program, Seattle Children’s Research Institute, Genethon (AFM-Téléthon), Sarepta Therapeutics Inc., REGENXBIO Inc., Abeona Therapeutics Inc., Rocket Pharmaceuticals Inc., Passage Bio Inc., Spark Therapeutics Inc., Takeda Rare Disease Research, Orchard Therapeutics plc, Avrobio Inc., bluebird bio Inc., JCR Pharmaceuticals Co. Ltd., Protalix BioTherapeutics Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc.

North America was the largest region in the farber's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the farber's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the farber's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the farber’s disease market by raising prices for enzyme replacement therapies, gene therapy components, and diagnostic reagents. Severe infantile and neurological forms are most affected, particularly in Europe and North America where rare-disease treatments are largely imported. Hospitals and specialty clinics experience increased therapy costs. On the positive side, tariffs are supporting local biotechnology manufacturing and rare-disease drug development.

The farber's disease market research report is one of a series of new reports that provides farber's disease market statistics, including farber's disease industry global market size, regional shares, competitors with a farber's disease market share, detailed farber's disease market segments, market trends and opportunities, and any further data you may need to thrive in the farber's disease industry. This farber's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Farber's disease is a rare genetic disorder caused by a deficiency of the enzyme acid ceramidase, resulting in the buildup of fatty materials in the body’s tissues. It is inherited in an autosomal recessive pattern and typically appears in infancy. Symptoms include joint deformities, subcutaneous nodules, and progressive neurological decline. The condition is progressive and often life-threatening, requiring multidisciplinary care and symptom management.

The main types of Farber's disease include classical and non-classical forms. Classical Farber's disease is the typical form, marked by early-onset symptoms such as joint deformities, subcutaneous nodules, and progressive neurological decline. Treatments include enzyme replacement therapy, symptomatic care, gene therapy, bone marrow transplant, and supportive care for clinical manifestations such as joint involvement, hearing loss, respiratory distress, and dermatological issues. Key end-users include hospitals, specialty clinics, diagnostic centers, and others.

The farber's disease market includes revenues earned by rehabilitation services, nutritional support services, and clinical trial access services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.